Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

PHOST'IN THERAPEUTICS

Home Clinical Trial Sponsors and OrganizationsPHOST'IN THERAPEUTICS

PHOST'IN THERAPEUTICS

104 RUE DE LA GALERA, Montpellier, Occitanie, France

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

2

1 active

Approvals

0

Total approvals

Agencies

0

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 1

2

100.0%

Trial Status Distribution

Active, not recruiting

1

50.0%

Recruiting

1

50.0%

Clinical Trials

Trials sponsored by this organization (2)

First-in-human Trial of PhOx430, a First-in-class Acetylglucosaminyltransferase V Inhibitor, in Advanced Solid Tumours

Active, not recruiting

Jul 2022149 participants

Phase I trial of the new drug PhOx430 (inhibitor of the enzyme glucosaminyltransferase V) in patients with advanced solid tumors; first test of a drug of this class in human beings.

149 participants

Approvals

No approval data available

News

No news articles found

On this page

Overview
Clinical Trials2
Approvals
News

Back to Organizations